(11) Statistics Canada. Findings from the 2005 National Survey of the Work and Health of Nurses. Statistics Canada . 11-12-2006.

(12) Caress SM, Steinemann AC. A review of a two-phase population study of multiple chemical sensitivities. Environ Health Perspect. 2003;111:1490-1497.

(13) Kreutzer R, Neutra RR, Lashuay N. Prevalence of people reporting sensitivities to chemicals in a population-based survey. Am J Epidemiol. 1999;150:1-12.

(14) Caress SM, Steinemann AC. National prevalence of asthma and chemical hypersensitivity: an examination of potential overlap. J Occup Environ Med. 2005;47:518-522.

(15) Meggs WJ, Dunn KA, Bloch RM, Goodman PE, Davidoff AL. Prevalence and nature of allergy and chemical sensitivity in a general population. Arch Environ Health. 1996;51:275-282.

(16) McKeown-Eyssen G, Baines C, Cole DE et al. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. Int J Epidemiol. 2004;33:971-978.

(17) Costa LG, Richter RJ, Li WF, Cole T, Guizzetti M, Furlong CE. Paraoxonase (PON 1) as a biomarker of susceptibility for organophosphate toxicity. Biomarkers. 2003;8:1-12.

(18) Furlong CE, Cole TB, Jarvik GP et al. Role of paraoxonase (PON1) status in pesticide sensitivity: genetic and temporal determinants. Neurotoxicology. 2005;26:651-659.

(19) Cole TB, Jampsa RL, Walter BJ et al. Expression of human paraoxonase (PON1) during development. Pharmacogenetics. 2003;13:357-364.

(20) Haley RW, Billecke S, La Du BN. Association of low PON1 type Q (type A) arylesterase activity with neurologic symptom complexes in Gulf War veterans. Toxicol Appl Pharmacol. 1999;157:227-233.